In an 83-year-old patient on dapagliflozin (Farxiga) 10 mg once daily with HbA1c decreasing from 7.8% to 7.7%, can another oral glucose‑lowering medication be added?

Yes, Add a GLP-1 Receptor Agonist to Farxiga in This 83-Year-Old Patient

For an 83-year-old patient on dapagliflozin 10 mg daily with HbA1c of 7.7% (minimal change from 7.8%), adding a long-acting GLP-1 receptor agonist is the preferred next step, provided the patient's kidney function (eGFR) is ≥15 mL/min/1.73 m² and they can manage injections. This recommendation prioritizes cardiovascular and kidney protection—which directly impact mortality and morbidity—over the modest additional glucose-lowering needed.

Why GLP-1 Receptor Agonists Are Preferred

The 2022 ADA/KDIGO consensus explicitly states that for patients with type 2 diabetes and CKD requiring additional glucose-lowering agents beyond metformin and/or SGLT2 inhibitors, addition of a long-acting GLP-1 receptor agonist is preferred 1. This is not merely about reaching an HbA1c target—GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE), slow eGFR decline, and reduce albuminuria 1. Notably, the cardiovascular benefit with liraglutide was significantly greater in patients with eGFR <60 mL/min/1.73 m² compared to those with preserved kidney function 1.

Specific Agent Selection

Choose among dulaglutide, liraglutide, or semaglutide (injectable)—all require no dose adjustment for kidney function and have proven cardiovascular outcomes 1. Weekly agents like dulaglutide or semaglutide reduce administration burden in older adults 2, 3. Avoid exenatide if eGFR <30 mL/min/1.73 m² 1.

Alternative Options (If GLP-1 RA Not Feasible)

If the patient cannot manage injections or tolerates GI side effects poorly, consider these alternatives in order:

1. DPP-4 Inhibitors

• Linagliptin requires no dose adjustment regardless of kidney function 1
• Sitagliptin, saxagliptin, and alogliptin require dose reduction based on eGFR 1
• Lower glucose-lowering efficacy than GLP-1 RAs but neutral on weight and minimal hypoglycemia risk 4
• No cardiovascular benefit demonstrated (only safety proven) 4

2. Low-Dose Pioglitazone

• No dose adjustment needed for kidney function 1
• High glucose-lowering efficacy and best evidence for glycemic durability 4
• Use 15-30 mg daily to mitigate weight gain and edema 4
• Avoid if history of heart failure, bone fracture risk, or bladder cancer concerns 4
• Recent data shows pioglitazone 30 mg added to dapagliflozin/metformin reduced HbA1c from 7.8% to 7.0% with 51.6% achieving HbA1c <7% 5

3. Avoid These Options in an 83-Year-Old

• Sulfonylureas/glinides: High hypoglycemia risk in older adults 6, 2
• Insulin intensification: Increases hypoglycemia and weight gain unless absolutely necessary 6, 2

Critical Considerations for This 83-Year-Old

Assess Kidney Function First

• Check eGFR before adding any medication 7, 8
• Dapagliflozin can be continued down to eGFR 25 mL/min/1.73 m² (or even <25 if already established) for cardiovascular/kidney benefits 1, 9
• GLP-1 RAs work down to eGFR 15 mL/min/1.73 m² 8

Evaluate Functional Status and Hypoglycemia Risk

• For older adults, individualized HbA1c targets based on health status are essential 6, 2
• If this patient has multiple comorbidities, dementia, or functional impairment, an HbA1c target of 7.5-8.0% may be more appropriate than aggressive lowering 6, 2
• The current HbA1c of 7.7% may actually be acceptable depending on overall health status 2

Practical Injection Considerations

• Assess visual, motor, and cognitive ability to self-administer injections 2, 3
• Weekly GLP-1 RAs reduce burden compared to daily injections 2, 3
• Oral semaglutide exists but has less cardiovascular outcome data 10

Common Pitfalls to Avoid

1. Don't add sulfonylureas or intensify insulin in an 83-year-old with HbA1c 7.7%—hypoglycemia risk far outweighs marginal glucose benefit 6, 2

2. Don't assume the patient needs tighter control—if they have significant comorbidities or frailty, HbA1c 7.5-8.0% may be optimal 6, 2

3. Don't stop dapagliflozin even if eGFR declines—cardiovascular and kidney benefits persist independent of glucose-lowering 1, 7, 8

4. Don't overlook volume status—older adults on dapagliflozin may need diuretic dose reduction when adding another agent 1, 7

5. Don't add therapy without reassessing the glycemic target—at age 83, preventing hypoglycemia and maintaining quality of life trumps aggressive HbA1c lowering 6, 2

Practical Algorithm

Step 1: Check current eGFR and assess functional/cognitive status

Step 2: Determine if HbA1c 7.7% truly requires intensification based on:

• Overall health status (healthy vs. complex/intermediate vs. very complex/poor health)
• Life expectancy
• Hypoglycemia history

Step 3: If intensification warranted:

• First choice: Add weekly GLP-1 RA (dulaglutide, semaglutide, or liraglutide if daily preferred)
• Second choice (if injections not feasible): Add linagliptin or low-dose pioglitazone (15-30 mg)
• Avoid: Sulfonylureas, glinides, or insulin intensification

Step 4: Follow up in 3 months to assess:

• HbA1c response
• Hypoglycemia episodes
• Weight changes
• GI tolerability (if GLP-1 RA)
• Volume status

1, 7, 1, 4, 6, 8, 2, 3, 9, 5